Last reviewed · How we verify
FERRIC AMMONIUM CITRATE
FERRIC AMMONIUM CITRATE is a drug. It is currently FDA-approved (first approved 1997).
Ferric Ammonium Citrate is a marketed iron replacement therapy with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term use. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | FERRIC AMMONIUM CITRATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1997 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy of Minayo Iron-rich Nutritional Gummies on Female Anemia, Skin Condition and Qi-blood Deficiency Syndrome (NA)
- Evaluation of the Effects of Routine Iron Supplementation in Children on Gastrointestinal Iron Losses (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FERRIC AMMONIUM CITRATE CI brief — competitive landscape report
- FERRIC AMMONIUM CITRATE updates RSS · CI watch RSS
Frequently asked questions about FERRIC AMMONIUM CITRATE
What is FERRIC AMMONIUM CITRATE?
FERRIC AMMONIUM CITRATE is a Small molecule drug.
When was FERRIC AMMONIUM CITRATE approved?
FERRIC AMMONIUM CITRATE was first approved on 1997.
What development phase is FERRIC AMMONIUM CITRATE in?
FERRIC AMMONIUM CITRATE is FDA-approved (marketed).